MGLL and myeloid sarcoma: Another recent study in a mouse model of MS [105] described a pharmacological strategy aimed at reducing CSPG deposition into the lesions by administering UCM03025, a new potent selective and reversible inhibitor of monoacylglycerol lipase (MagL), the enzyme that accounts for 2-arachidonoylglycerol (2-AG) degradation.